Artelo Biosciences Secures Bridge Financing Through Note Issuance

Artelo Biosciences ( (ARTL) ) has issued an update.

On March 12, 2026, Artelo Biosciences, Inc. entered into separate securities purchase agreements with Vanquish Funding Group Inc. and Boot Capital LLC, issuing 12% bridge notes with aggregate principal amounts of $237,300 and $113,000, respectively, including original issue discounts. The notes, which mature on January 15, 2027 and can be prepaid without penalty, provide Artelo with $310,000 in gross proceeds earmarked for general working capital, while imposing strict default provisions that allow investors, upon an event of default, to demand 150% of outstanding amounts and potentially convert debt into common stock at a discounted price, subject to a 4.99% ownership cap and reliance on private placement exemptions under U.S. securities law.

The financing structure underscores Artelo’s reliance on higher-cost bridge funding to support its operations, signaling both immediate liquidity support and heightened financial risk for existing shareholders through possible dilution in a default scenario. Because the notes are unregistered and sold only to accredited investors under Regulation D exemptions, trading in any resulting securities will be constrained, concentrating risk and potential upside among a limited group of institutional stakeholders.

The most recent analyst rating on (ARTL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Spark’s Take on ARTL Stock

According to Spark, TipRanks’ AI Analyst, ARTL is a Neutral.

The score is held down primarily by weak financial fundamentals (no revenue, continued losses/cash burn, and negative equity). Technicals are only neutral and do not offset the longer-term downtrend, while valuation lacks earnings and dividend support. Recent events add risk due to going-concern and Nasdaq compliance pressures, partially balanced by added financing flexibility.

To see Spark’s full report on ARTL stock, click here.

More about Artelo Biosciences

Artelo Biosciences, Inc. is a biopharmaceutical company focused on developing therapeutics, with its capital-raising activities centered on issuing debt securities to institutional investors. The company accesses private financing through structured bridge notes, targeting accredited investors in exempt offerings under U.S. securities regulations to fund its ongoing operations and working capital needs.

Average Trading Volume: 26,981

Technical Sentiment Signal: Sell

Current Market Cap: $3.44M

For an in-depth examination of ARTL stock, go to TipRanks’ Overview page.